Fundacja Progress AND Business (KRS 0000155141, NIP 6770011333) is a Polish company, headquartered in Kraków, Małopolskie voivodeship. FUNDACJA PROGRESS AND BUSINESS operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since April 2, 2003.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Fundacja Progress AND Business
Identity
- Name
- Fundacja Progress AND Business
- Legal form
- FUNDACJA
- Founded
- April 2, 2003
- Registry status as of
- November 21, 2025
- Latest entry
- September 16, 2025
- Founding act
- 25.01.1991R; ZMIANA STATUTU FUNDACJI Z DNIA 21.12.2001: OD §1 DO §6, DODANO: §7, ZMIENIONO DOTYCHCZASOWE OD §7 DO §14 UC…
Articles of association history (2)
- January 25, 1991: 25.01.1991R; ZMIANA STATUTU FUNDACJI Z DNIA 21.12.2001: OD §1 DO §6, DODANO: §7, ZMIENIONO DOTYCHCZASOWE OD §7 DO §14 UCHWAŁA Z DNIA 20.12.2002R; ZMIENIONO: §2-11, §13, §15.
- June 29, 2015: 29.06.2015 R., ZMIANA: § 3 PKT 6, § 4 PKT 3; § 7 PKT 1,2,3,6; § 8 PKT 4,6,7; § 9 PKT 7; § 10 PKT 1,4; § 11 PKT 8; § 15 PKT 2,3WYKREŚLENIE PKT 5, ZMIANA NUMERACJI PKT 6;ZAŁĄCZNIKA DO STATUTU
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- JULIUSZA LEA, 12 B, 30-048, KRAKÓW, POLSKA
- Voivodeship
- MAŁOPOLSKIE
- District
- KRAKÓW
- OFFICE@PBF.PL
- Website
- HTTP://WWW.PBF.PL
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Fundacja Progress AND Business
Credibility rating
54.7 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/23 yrs
Board changes
2
2/23 yrs
PKD changes
1
1/23 yrs
Name changes
0
0/23 yrs
Data from 23 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (55/100)
Trend: stable (-0.4 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Fundacja Progress AND Business
Founded
April 2, 2003
23 years in operation
Legal form
FUNDACJA
Registry: RejP
Headquarters
KRAKÓW
MAŁOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
N/A
Shareholders
N/A
Board
2 people
Sup. board: 10
Filed years
7 years
2018–2024
Registry entries
28
latest: September 16, 2025
Revenue
N/A
2024
Net profit
N/A
2024
Assets
2.5 M PLN
2024
Equity
1.4 M PLN
2024
Valuation
1.8 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
LEI Code
Global Legal Entity Identifier (LEI) for Fundacja Progress AND Business from the GLEIF database - code, status, BIC, registered address and registration details.
LEI code
259400I6OS5OJ0I48A68
Legal name
Fundacja Progress and Business
Registry number
0000155141
Jurisdiction
PL
Registered address
Kraków Juliusza Lea 12B30-048 KrakówPLHeadquarters
Kraków Juliusza Lea 12B/430-048 KrakówPLGLEIF registration
- Registration status
- LAPSED
- First registered
- 2018-01-03
- Last updated
Reviews
Rate business credibility - Fundacja Progress AND Business.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
